Interleukin-1 receptor-associated kinase 1 (IRAK1) (IRAK1)

Interleukin-1 receptor-associated kinase 1 (IRAK1) is a critical serine/threonine kinase that mediates signaling from the Interleukin-1 receptor (IL-1R) and various Toll-like receptors (TLRs) [1]. Upon receptor activation, IRAK1 is recruited to the receptor complex via the adapter protein MyD88, where it undergoes rapid phosphorylation and subsequently activates downstream effectors such as TRAF6, leading to the activation of the NF-kappaB and MAPK pathways [1][4]. This signaling cascade is essential for the production of pro-inflammatory cytokines and the initiation of the innate immune response. Overexpression or constitutive activation of IRAK1 is strongly associated with the pathogenesis of chronic inflammatory diseases, autoimmune disorders, and several malignancies, including myelodysplastic syndromes (MDS) and breast cancer [2][4]. Therapeutic targeting of IRAK1 involves small-molecule kinase inhibitors, many of which are being evaluated in clinical trials for hematologic cancers and inflammatory conditions [3]. Additionally, targeting IRAK1 at the transcript level using antisense oligonucleotides or siRNA (mRNA targeting) is an emerging strategy to reduce protein expression and dampen pathological signaling in overactive immune states [2].

Other names

IRAKPellemPelleInterleukin-1 receptor-associated kinase 1 mRNA

Kinase inhibition, mRNA degradation (via antisense oligonucleotides or siRNA), Targeted protein degradation (PROTACs)